Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results

Data demonstrates BT-001 was durable with A1c reductions continuing to improve after 180 days of treatment On track to submit a de novo classification request with FDA for BT-001 in third quarter of 2022 Company to host conference call and webcast